Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vermorken, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vermorken, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:303-306, 1993
© 1993 European Society for Medical Oncology

research-article

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer

J. B. Vermorken1,, S. Gundersen2, M. Clavel3, J. F. Smyth4, P. Dodion5, J. Renard6, S. B. Kaye7 and For the EORTC Early Clinical Trials Group and the EORTC Data Center

1Free University Hospital, Amsterdam The Netherlands
2Det Norske Radium Hospital Oslo, Norway
3Centre Leon Bérard Lyon, France
4University of Edinburgh Edinburgh, Great Britain
5Inst. Jules Bordet
6EORTC Data Center Brussels, Belgium
7University of Glasgow Glasgow, Great Britain

Correspondence to: J. B. Vermorken, MD, PhD Department of Oncology Free University Hospital De Boelelaan 1117 1081 HV Amsterdam, The Netherlands

BACKGROUND:: The observed activity of cisplatin in breast cancer and its unattractive toxicity profile in palliative treatment warranted further study of platinum analogues in this disease.

PATIENTS AND METHODS:: Sixty-two patients with recurrent or metastatic breast cancer, 61 of whom had been previously treated with chemotherapy, were randomly assigned to therapy with either iproplatin (n = 32) or carboplatin (n = 30). Both platinum analogues were administered intravenously, iproplatin at a dose of 240 mg/m2 every 4 weeks and carboplatin at a dose of 450 mg/m2 every 5 weeks.

RESULTS:: Only two patients responded to iproplatin (7%) for durations of 21 and 61 weeks, and one patient responded to carboplatin (3%) for a duration of 64 weeks. All responses were complete. At the given dose schedules carboplatin was more myelosuppressive than iproplatin. Non-hematologic toxicities included nausea and vomiting (93% vs. 90%), diarrhea (20% vs. 10%) and hemorrhage (16% vs. 10%) for iproplatin and carboplatin, respectively. Two patients developed alopecia with carboplatin. No renal toxicity was observed.

CONCLUSIONS:: Both iproplatin and carboplatin have limited activity in previously treated women with advanced breast cancer when given in conventional dosages.

breast cancer, iproplatin, carboplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.